CG
KLRS

Cutler Group’s Kalaris Therapeutics KLRS Stock Holding History

Cutler Group’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-78
Closed -$14K – 5398
2022
Q3 		$14K Sell
78
-39
-33% -$6.08K ﹤0.01% 2903
2022
Q2 		$10K Buy
+117
New +$12.3K ﹤0.01% 3232
2020
Q4 		– Sell
-22
Closed -$13K – 5634
2020
Q3 		$13K Buy
+22
New +$15K ﹤0.01% 2814

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Cutler Group's KLRS Position: Q4 2022 in Review

Cutler Group sold out of Kalaris Therapeutics (KLRS) in Q4 2022, closing a stake of 78 shares — an estimated $14K sold.

Cutler Group first reported a position in KLRS in Q3 2020 and held it in 3 quarters. The position peaked at $14K in Q3 2022. 85 funds tracked by Wall St. Rank hold KLRS as of Q4 2022.

  • Cutler Group reported no remaining Kalaris Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Cutler Group sold 78 Kalaris Therapeutics shares in Q4 2022, an estimated $14K.
  • Cutler Group first reported a position in Kalaris Therapeutics in Q3 2020 and held it in 3 quarters.
  • Cutler Group's Kalaris Therapeutics position peaked at $14K in Q3 2022.
  • 85 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2022.

Based on Cutler Group's 13F filing for Q4 2022, filed 7 Feb 2023.